|Fluticasone||Inhaled corticosteroid (ICS)|
|Formoterol||Long-acting beta agonist (LABA)|
|Trade names||Flutiform, Iffeza, others|
|Other names||Fluticasone propionate/formoterol fumarate|
|Side effects||Dry mouth, trouble sleeping, rash|
Fluticasone/formoterol, sold under the brand name Flutiform among others, is a combination medication used in the long-term treatment of asthma. It is used by breathing in two puffs of the medication twice per day.
The combination is approved for medical use in a number of countries in Europe in 2012. It is also approved in Australia, South Korea, and Japan. It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide/formoterol. In the United Kingdom 120 doses costs the NHS about £28 as of 2023.
- "Fluticasone with formoterol". NICE. Archived from the original on 13 September 2023. Retrieved 10 September 2023.
- "Flutiform". European Medicines Agency. 17 September 2018. Archived from the original on 18 April 2021. Retrieved 10 September 2023.
- Dissanayake, S; Grothe, B; Kaiser, K (December 2012). "Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma". Respiratory medicine. 106 Suppl 1: S20-8. doi:10.1016/S0954-6111(12)70006-9. PMID 23273163.
- Prosser, TR; Bollmeier, SG (2015). "Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma". Therapeutics and clinical risk management. 11: 889–99. doi:10.2147/TCRM.S55116. PMID 26082638.
- World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- "Fluticasone with formoterol Medicinal forms". NICE. Archived from the original on 13 September 2023. Retrieved 10 September 2023.